<DOC>
	<DOCNO>NCT02470468</DOCNO>
	<brief_summary>The purpose study compare efficacy DCVAC/LuCa + chemotherapy +/- immune enhancer vs. chemotherapy alone patient stage IV NSCLC , measure progression free survival ( PFS ) .</brief_summary>
	<brief_title>Evaluation Safety Efficacy DCVAC/LuCa ( Immunotherapy Lung Cancer ) Patients With Metastatic Lung Cancer</brief_title>
	<detailed_description>The purpose study compare efficacy DCVAC/LuCa + chemotherapy +/- immune enhancer vs. Standard Care chemotherapy alone patient stage IV NSCLC , measure progression free survival ( PFS ) .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<criteria>1 . Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) either adenomatous squamous cell carcinoma differentiation ; mixed tumor categorize predominant cell type . 2 . Advanced NSCLC ( stage IV unresectable disease ) 3 . Patients must measurable nonmeasurable disease 4 . Patients ( male female ) ≥ 18 year 5 . Eastern Cooperative Oncology Group ( ECOG ) Performance status 01 6 . Patients must recover toxicity prior therapy ( e.g . surgery , radiotherapy , therapy disease NSCLC ) . Recovery define less equal grade 2 toxicity accord ( except alopecia ) NCI CTCAE 7 . Laboratory criteria 7.1 Platelet count least 100,000/mm3 ( 100 x 109/L ) 7.2 White blood cell ( WBC ) great 4,000/mm3 ( 4.0 x109/L ) 7.3 Hemoglobin ( Hb ) least 9g/dL ( 90 g/L ) 7.4 Total bilirubin level ≤1.5mg/dL ( benign hereditary hyperbilirubinemia , e.g. , Gilbert´s syndrome permit ) 7.5 Serum alanine aminotransferase aspartate aminotransferase ≤ 5 time upper limit normal ( ULN ) 7.6 Serum creatinine ≤ 1.5 time upper limit normal ( ULN ) 8 . Women childbearing potential sexually active male must agree use accepted effective method contraception ( hormonal barrier method , abstinence ) prior study entry duration treatment plus 3 month . 9 . Signed informed consent include patient 's ability comprehend content . ( Consent genetic test condition participation clinical trial ) 1 . Prior chemotherapy stage IV NSCLC 2 . Immunotherapy , monoclonal antibody receive within 4 week prior randomization 3 . Patients comorbidities 3.1 Patients indicated chemotherapy treatment first line Standard Care chemotherapy ( carboplatin/paclitaxel ) 3.2 Active malignancy NSCLC 3.3 Known central nervous system ( CNS ) metastases 3.4 Any disease require chronic steroid immunosuppressive therapy 3.5 HIV positive 3.6 Active hepatitis B ( HBV ) and/or C ( HCV ) , active syphilis 3.7 Ongoing/active significant infection severe medical condition 3.8 Preexisting thyroid disease unless controlled conventional treatment 3.9 Clinically significant cardiovascular disease include : 3.9.1 Uncontrolled congestive heart failure 3.9.2 Unstable angina pectoris 3.9.3 Uncontrolled severe cardiac arrhythmia 3.9.4 Myocardial infarction within 6 month prior randomization 3.10 Psychiatric illness/social situation would limit compliance study requirement 4 . Pregnant breast feed woman 5 . Participation clinical trial use experimental therapy within last 4 week prior randomization 6 . Contra indication treatment hydroxychloroquine , know G6PD deficiency ( anamnestic information , test necessary ) psoriasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>Metastatic</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Biological</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Vaccine</keyword>
</DOC>